应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
RMD 瑞思迈
未开盘 08-25 16:00:00 EDT
236.59
+4.14
+1.78%
盘后
236.59
+0.00
0.00%
19:59 EDT
最高
238.37
最低
231.89
成交量
176.11万
今开
232.22
昨收
232.45
日振幅
2.79%
总市值
341.29亿
流通市值
339.48亿
总股本
1.44亿
成交额
4.16亿
换手率
1.23%
流通股本
1.43亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
23Xi车队纳斯卡车手泰勒·雷迪克公开睡眠呼吸暂停诊断,携手瑞思迈助力公众识别症状
美股速递 · 08-25 21:01
23Xi车队纳斯卡车手泰勒·雷迪克公开睡眠呼吸暂停诊断,携手瑞思迈助力公众识别症状
瑞思迈宣布Carol Burt出任首席董事,Ron Taylor计划退休
美股速递 · 08-18
瑞思迈宣布Carol Burt出任首席董事,Ron Taylor计划退休
异动解读|瑞思迈盘中下跌7.69%,财报超预期但营收增速放缓遭多家机构下调评级
行情直击 · 08-07
异动解读|瑞思迈盘中下跌7.69%,财报超预期但营收增速放缓遭多家机构下调评级
瑞思迈公布第四季度业绩后股价下跌7.7%。
智通财经 · 08-07
瑞思迈公布第四季度业绩后股价下跌7.7%。
异动解读 | 财报超预期但增长放缓遭机构下调评级,瑞思迈夜盘大跌8.78%
异动解读 · 08-07
异动解读 | 财报超预期但增长放缓遭机构下调评级,瑞思迈夜盘大跌8.78%
异动解读|瑞思迈盘前下跌8.41%,财报超预期但营收增速放缓引发市场担忧
行情直击 · 08-07
异动解读|瑞思迈盘前下跌8.41%,财报超预期但营收增速放缓引发市场担忧
异动解读 | 瑞思迈夜盘大跌6.07%,财报超预期但营收增速放缓引发市场担忧
异动解读 · 08-07
异动解读 | 瑞思迈夜盘大跌6.07%,财报超预期但营收增速放缓引发市场担忧
异动解读|瑞思迈夜盘下跌6.15%,业绩超预期但营收增速放缓引发市场担忧
行情直击 · 08-07
异动解读|瑞思迈夜盘下跌6.15%,业绩超预期但营收增速放缓引发市场担忧
异动解读 | 瑞思迈盘后大跌6.83%,业绩超预期但增长放缓引发市场担忧
异动解读 · 08-07
异动解读 | 瑞思迈盘后大跌6.83%,业绩超预期但增长放缓引发市场担忧
异动解读|瑞思迈盘后下跌5.03%,业绩虽超预期但增长放缓引发市场担忧
行情直击 · 08-07
异动解读|瑞思迈盘后下跌5.03%,业绩虽超预期但增长放缓引发市场担忧
瑞思迈:2027财年计划向股东返还超18.5亿美元,并宣布季度股息上调10%至0.66美元
美股速递 · 08-07
瑞思迈:2027财年计划向股东返还超18.5亿美元,并宣布季度股息上调10%至0.66美元
克利夫兰医疗设备公司:PTAB在五分之四的诉讼中裁定公司未能证明争议专利主张不可授权
美股速递 · 07-14
克利夫兰医疗设备公司:PTAB在五分之四的诉讼中裁定公司未能证明争议专利主张不可授权
异动解读|瑞思迈盘中下跌5.61%,花旗下调评级至中性引发抛压
行情直击 · 07-13
异动解读|瑞思迈盘中下跌5.61%,花旗下调评级至中性引发抛压
异动解读|瑞思迈盘前下跌5.19%,花旗下调评级至中性
行情直击 · 07-13
异动解读|瑞思迈盘前下跌5.19%,花旗下调评级至中性
异动解读|瑞思迈盘中下跌5.29%,宣布出售MatrixCare业务叠加RBC下调目标价
行情直击 · 07-08
异动解读|瑞思迈盘中下跌5.29%,宣布出售MatrixCare业务叠加RBC下调目标价
瑞思迈重申2026财年非GAAP毛利率、销售管理费用、研发支出及非GAAP税率展望——SEC文件披露
美股速递 · 07-08
瑞思迈重申2026财年非GAAP毛利率、销售管理费用、研发支出及非GAAP税率展望——SEC文件披露
异动解读|瑞思迈盘中上涨5.01%,收购Noctrix扩展睡眠产品线叠加财报预期提振
行情直击 · 07-07
异动解读|瑞思迈盘中上涨5.01%,收购Noctrix扩展睡眠产品线叠加财报预期提振
大摩下调瑞思迈 (RMD) 投资评级 指减肥药与竞品入市双重压制其增长空间
金吾财讯 · 06-17
大摩下调瑞思迈 (RMD) 投资评级 指减肥药与竞品入市双重压制其增长空间
瑞思迈斥资3.4亿美元收购Noctrix Health,安杰利尼风投迎来首笔投资退出
美股速递 · 06-03
瑞思迈斥资3.4亿美元收购Noctrix Health,安杰利尼风投迎来首笔投资退出
异动解读|瑞思迈盘中下跌5.08%,宣布重大收购切入新赛道引发市场担忧
行情直击 · 05-30
异动解读|瑞思迈盘中下跌5.08%,宣布重大收购切入新赛道引发市场担忧
加载更多
公司概况
公司名称:
瑞思迈
所属市场:
NYSE
上市日期:
--
主营业务:
ResMed Inc.是一家特拉华州公司,成立于1994年3月。该公司在医疗设备和基于云的软件应用程序的开发、制造、分销和营销方面处于全球领先地位,这些应用程序诊断、治疗和管理呼吸系统疾病,包括睡眠呼吸障碍、慢性阻塞性肺病、神经肌肉疾病和其他慢性疾病。该公司的产品和解决方案旨在改善患者的生活质量,减少慢性病的影响,并降低医疗保健成本,因为全球医疗保健系统继续推动从医院到家庭和低成本环境的护理转移。该公司基于云的数字软件健康应用程序以及设备旨在提供联网护理,以改善患者的治疗效果并提高客户的效率。
发行价格:
--
{"stockData":{"symbol":"RMD","market":"US","secType":"STK","nameCN":"瑞思迈","latestPrice":236.59,"timestamp":1787688000000,"preClose":232.45,"halted":0,"volume":1761085,"hourTrading":{"tag":"盘后","latestPrice":236.59,"preClose":236.59,"latestTime":"19:59 EDT","volume":20479,"amount":4845011.29,"timestamp":1787702393242,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.017810281781028243,"floatShares":143488195,"shares":144252306,"eps":10.43,"marketStatus":"未开盘","change":4.14,"latestTime":"08-25 16:00:00 EDT","open":232.22,"high":238.37,"low":231.885,"amount":416345589.46125,"amplitude":0.027898,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":10.43,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1787731200000},"marketStatusCode":0,"adr":0,"adrRate":0,"exchange":"NYSE","adjPreClose":232.45,"dividendRate":0.010144,"preHourTrading":{"tag":"盘前","latestPrice":231,"preClose":232.45,"latestTime":"09:18 EDT","volume":31,"amount":7166.48483,"timestamp":1787663908908,"change":-1.45,"changeRate":-0.006238,"amplitude":0.008604},"postHourTrading":{"tag":"盘后","latestPrice":236.59,"preClose":236.59,"latestTime":"19:59 EDT","volume":20479,"amount":4845011.29,"timestamp":1787702393242,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.328043,"impliedVol":0.29,"impliedVolPercentile":0.252},"requestUrl":"/m/hq/s/RMD","defaultTab":"news","newsList":[{"id":"1197821832","title":"23Xi车队纳斯卡车手泰勒·雷迪克公开睡眠呼吸暂停诊断,携手瑞思迈助力公众识别症状","url":"https://stock-news.laohu8.com/highlight/detail?id=1197821832","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1197821832?lang=zh_cn&edition=full","pubTime":"2026-08-25 21:01","pubTimestamp":1787662869,"startTime":"0","endTime":"0","summary":"23Xi车队的纳斯卡车手泰勒·雷迪克近日透露了自己患有睡眠呼吸暂停的状况,并与医疗设备公司瑞思迈达成合作,共同推动公众对这一常见却常被忽视的健康问题的认知。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00B5TLWC47.USD","LGHT","LU2008162690.USD","BK4567","BK4548","RMD","BK4504","LU2177674079.SGD","BK4585","BK4082","LU0170899867.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1117336876","title":"瑞思迈宣布Carol Burt出任首席董事,Ron Taylor计划退休","url":"https://stock-news.laohu8.com/highlight/detail?id=1117336876","media":"美股速递","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1117336876?lang=zh_cn&edition=full","pubTime":"2026-08-18 04:12","pubTimestamp":1786997533,"startTime":"0","endTime":"0","summary":"瑞思迈(ResMed)今日发布重大人事变动消息。公司正式宣布,任命Carol Burt为首席董事,这一决定即刻生效。与此同时,现任董事Ron Taylor的退休计划也被提上日程,预计将在不久的将来正式卸任。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RMD","IE00B5TLWC47.USD","LGHT","BK4567","BK4548","LU0170899867.USD","LU2008162690.USD","BK4585","BK4588","LU2177674079.SGD","BK4504","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163789317","title":"异动解读|瑞思迈盘中下跌7.69%,财报超预期但营收增速放缓遭多家机构下调评级","url":"https://stock-news.laohu8.com/highlight/detail?id=1163789317","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163789317?lang=zh_cn&edition=full","pubTime":"2026-08-07 21:41","pubTimestamp":1786110093,"startTime":"0","endTime":"0","summary":"8月7日,瑞思迈盘中下跌7.69%,报204.075美元/股,成交额7489.23万美元。消息面上,公司发布第四财季业绩,调整后每股收益2.95美元,高于市场预期的2.89美元;营收14.6亿美元符合预期,同比增长8.1%。摩根士丹利将其降至等权重,警示减肥药物与竞品入市将长期压制增长空间;RBC、花旗等机构也下调评级或目标价。公司同时宣布下一财年向股东返还超18.5亿美元,季度股息上调10%至每股0.66美元,但未能扭转市场悲观情绪。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"瑞思迈盘中下跌7.69%,财报超预期但营收增速放缓遭多家机构下调评级","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657649233","title":"瑞思迈公布第四季度业绩后股价下跌7.7%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2657649233","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657649233?lang=zh_cn&edition=full","pubTime":"2026-08-07 21:32","pubTimestamp":1786109569,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LU2177674079.SGD","RMD","LU0170899867.USD","BK4082","BK4504","LGHT","IE00B5TLWC47.USD","LU2008162690.USD","BK4567","BK4585","BK4548","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185944228","title":"异动解读 | 财报超预期但增长放缓遭机构下调评级,瑞思迈夜盘大跌8.78%","url":"https://stock-news.laohu8.com/highlight/detail?id=1185944228","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185944228?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:06","pubTimestamp":1786089997,"startTime":"0","endTime":"0","summary":"瑞思迈在夜盘交易时段大跌8.78%,引发市场广泛关注。公司同时公布2027财年计划向股东返还超18.5亿美元,并将季度股息上调10%至每股0.66美元。尽管业绩小幅超预期,股价仍承压下行。此前多家机构已下调对公司的评级与目标价。摩根士丹利将其降至等权重,警示减肥药物与竞品入市将长期压制增长空间;花旗、RBC等机构也在近期下调评级。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143190566","title":"异动解读|瑞思迈盘前下跌8.41%,财报超预期但营收增速放缓引发市场担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1143190566","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1143190566?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:04","pubTimestamp":1786089842,"startTime":"0","endTime":"0","summary":"8月7日,瑞思迈盘前下跌8.41%,报204.0美元/股,成交额2.9万美元。公司同时公布计划在下一财年向股东返还超18.5亿美元,并将季度股息上调10%至每股0.66美元。当前营收增速已从此前双位数区间回落至约8%,与近三年19%的每股收益复合增速形成明显落差,市场对未来增长前景存疑。此外,Astral现场安全通知相关费用约4190万美元压低了GAAP利润率,进一步影响市场情绪。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"瑞思迈盘前下跌8.41%,财报超预期但营收增速放缓引发市场担忧","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1163386970","title":"异动解读 | 瑞思迈夜盘大跌6.07%,财报超预期但营收增速放缓引发市场担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1163386970","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1163386970?lang=zh_cn&edition=full","pubTime":"2026-08-07 08:05","pubTimestamp":1786061108,"startTime":"0","endTime":"0","summary":"瑞思迈在夜盘交易时段股价大跌6.07%,引发市场广泛关注。消息面上,公司发布了第四财季业绩,调整后每股收益为2.95美元,高于市场预期的2.89美元,营收14.6亿美元符合市场预期,同比增长8.1%。公司同时公布2027财年计划向股东返还超18.5亿美元,并将季度股息上调10%至每股0.66美元。尽管业绩小幅超预期,股价仍承压下行。此外,Astral现场安全通知相关费用约4190万美元也压低了GAAP利润率,进一步影响了市场情绪。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1148573397","title":"异动解读|瑞思迈夜盘下跌6.15%,业绩超预期但营收增速放缓引发市场担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1148573397","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1148573397?lang=zh_cn&edition=full","pubTime":"2026-08-07 08:01","pubTimestamp":1786060902,"startTime":"0","endTime":"0","summary":"8月7日,瑞思迈夜盘下跌6.15%,报209.51美元/股,成交额4192.1美元。消息面上,公司发布第四财季业绩,调整后每股收益2.95美元,高于市场预期的2.89美元;营收14.6亿美元符合预期,同比增长8.1%。公司同时公布计划在下一财年向股东返还超18.5亿美元,并将季度股息上调10%至每股0.66美元。瑞思迈是全球领先的睡眠与呼吸医疗设备公司,专注于诊断、治疗和管理呼吸系统疾病,产品覆盖CPAP设备及基于云的数字健康应用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"瑞思迈夜盘下跌6.15%,业绩超预期但营收增速放缓引发市场担忧","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191177256","title":"异动解读 | 瑞思迈盘后大跌6.83%,业绩超预期但增长放缓引发市场担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1191177256","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191177256?lang=zh_cn&edition=full","pubTime":"2026-08-07 05:12","pubTimestamp":1786050737,"startTime":"0","endTime":"0","summary":"瑞思迈盘后股价大跌6.83%,引发市场广泛关注。消息面上,公司发布了第四财季业绩,调整后每股收益为2.95美元,高于市场预期的2.89美元,营收14.6亿美元符合市场预期,同比增长8.1%。公司同时公布2027财年计划向股东返还超18.5亿美元,并将季度股息上调10%至每股0.66美元。尽管业绩小幅超预期,股价仍承压下行。当前营收增速已从此前双位数区间回落至约8%,与近三年19%的每股收益复合增速形成落差,市场对未来增长前景存疑,成为股价下跌的主要原因。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["RMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191528381","title":"异动解读|瑞思迈盘后下跌5.03%,业绩虽超预期但增长放缓引发市场担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1191528381","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1191528381?lang=zh_cn&edition=full","pubTime":"2026-08-07 05:01","pubTimestamp":1786050083,"startTime":"0","endTime":"0","summary":"8月7日,瑞思迈盘后下跌5.03%,报212.0美元/股,成交额245.92万美元。公司同时公布2027财年计划向股东返还超18.5亿美元,并将季度股息上调10%至每股0.66美元。尽管业绩小幅超预期,股价仍承压下行。瑞思迈是全球领先的睡眠与呼吸医疗设备公司,专注于诊断、治疗和管理呼吸系统疾病,产品覆盖CPAP设备及基于云的数字健康应用。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152074696","title":"瑞思迈:2027财年计划向股东返还超18.5亿美元,并宣布季度股息上调10%至0.66美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1152074696","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1152074696?lang=zh_cn&edition=full","pubTime":"2026-08-07 04:42","pubTimestamp":1786048931,"startTime":"0","endTime":"0","summary":"瑞思迈(ResMed)近日发布指引,计划在2027财年向股东返还超过18.5亿美元的资金。与此同时,该公司宣布将季度股息上调10%,至每股0.66美元。这一举措充分彰显了瑞思迈对股东回报的坚定承诺,也反映出其稳健的现金流实力和未来增长的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LGHT","RMD","BK4504","BK4082","BK4588","LU2177674079.SGD","LU0170899867.USD","BK4585","BK4548","BK4567","IE00B5TLWC47.USD","LU2008162690.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1195295414","title":"克利夫兰医疗设备公司:PTAB在五分之四的诉讼中裁定公司未能证明争议专利主张不可授权","url":"https://stock-news.laohu8.com/highlight/detail?id=1195295414","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1195295414?lang=zh_cn&edition=full","pubTime":"2026-07-14 04:29","pubTimestamp":1783974574,"startTime":"0","endTime":"0","summary":"克利夫兰医疗设备公司披露,美国专利审判和上诉委员会(PTAB)在针对其五项专利诉讼中的四项,作出了对其有利的裁决,认定公司未能成功证明相关争议专利主张不具备可专利性。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2177674079.SGD","RMD","LU0170899867.USD","BK4082","BK4504","LGHT","IE00B5TLWC47.USD","LU2008162690.USD","BK4567","BK4585","BK4548","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186598906","title":"异动解读|瑞思迈盘中下跌5.61%,花旗下调评级至中性引发抛压","url":"https://stock-news.laohu8.com/highlight/detail?id=1186598906","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186598906?lang=zh_cn&edition=full","pubTime":"2026-07-13 21:38","pubTimestamp":1783949931,"startTime":"0","endTime":"0","summary":"7月13日,瑞思迈盘中下跌5.61%,报196.975美元/股,成交额3231.34万美元。消息面上,花旗将瑞思迈评级从\"买入\"下调至\"中性\",目标价定为34澳元,成为近期机构连续下调中最具冲击力的一次。此前,花旗曾于6月中旬将美股目标价从340美元降至270美元并维持买入,此次进一步降级至中性,反映对公司前景预期的实质性恶化。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119046769","title":"异动解读|瑞思迈盘前下跌5.19%,花旗下调评级至中性","url":"https://stock-news.laohu8.com/highlight/detail?id=1119046769","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1119046769?lang=zh_cn&edition=full","pubTime":"2026-07-13 21:27","pubTimestamp":1783949262,"startTime":"0","endTime":"0","summary":"7月13日,瑞思迈盘前下跌5.19%,报193.01美元/股,成交额37.32万美元。消息面上,花旗将瑞思迈评级从\"买入\"下调至\"中性\",目标价定为34澳元,为近期机构连续下调中最具冲击力的一次。此前,Jefferies已将目标价从240美元下调至225美元,Jarden将澳股目标价从42.70澳元降至40.20澳元。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144489423","title":"异动解读|瑞思迈盘中下跌5.29%,宣布出售MatrixCare业务叠加RBC下调目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=1144489423","media":"行情直击","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144489423?lang=zh_cn&edition=full","pubTime":"2026-07-08 21:59","pubTimestamp":1783519151,"startTime":"0","endTime":"0","summary":"7月8日,瑞思迈盘中下跌5.29%,报208.52美元/股,成交额4511.7万美元。消息面上,公司宣布同意出售旗下MatrixCare业务,以聚焦高增长的睡眠及互联护理市场;同日RBC Capital将公司目标价从321美元大幅下调至276美元,维持跑赢大盘评级。此前一日公司因Noctrix收购消息推动曾上涨5.01%,当前回吐全部涨幅。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118172917","title":"瑞思迈重申2026财年非GAAP毛利率、销售管理费用、研发支出及非GAAP税率展望——SEC文件披露","url":"https://stock-news.laohu8.com/highlight/detail?id=1118172917","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1118172917?lang=zh_cn&edition=full","pubTime":"2026-07-08 05:31","pubTimestamp":1783459908,"startTime":"0","endTime":"0","summary":"瑞思迈在提交给美国证券交易委员会(SEC)的最新文件中,重申了其对2026财年多项关键财务指标的非公认会计准则(Non-GAAP)展望。公司确认的预期目标范围涵盖非GAAP毛利率、销售管理费用(SG&A)、研发(R&D)支出以及非GAAP税率。\n此举表明管理层对既定运营与财务计划保持信心,预计相关成本结构与盈利能力将沿预设轨迹发展。市场通常关注此类重申,视其为业务稳定性和预测能见度的信号。投资者可借此评估公司在呼吸与睡眠医疗设备领域的持续运营效率及长期财务健康度。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B5TLWC47.USD","BK4567","BK4585","BK4588","BK4504","BK4082","LU2008162690.USD","LGHT","LU0170899867.USD","BK4548","LU2177674079.SGD","RMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144595286","title":"异动解读|瑞思迈盘中上涨5.01%,收购Noctrix扩展睡眠产品线叠加财报预期提振","url":"https://stock-news.laohu8.com/highlight/detail?id=1144595286","media":"行情直击","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1144595286?lang=zh_cn&edition=full","pubTime":"2026-07-07 02:11","pubTimestamp":1783361500,"startTime":"0","endTime":"0","summary":"7月7日,瑞思迈盘中上涨5.01%,报220.17美元/股,成交额4.26亿美元。消息面上,公司近期以3.4亿美元完成对Noctrix Health的收购,将FDA批准的非药物不宁腿综合征疗法纳入产品组合,拓展至第三大睡眠障碍治疗领域。该疗法将接入瑞思迈全球超2700万台云端互联设备生态,形成商业协同。此外,公司已公告将于8月6日发布第四季度财报,市场预期每股收益2.9美元。此前股价受摩根士丹利下调评级至等权重影响一度跌至52周低位附近,目前呈现明显反弹修复态势。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RMD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644749109","title":"大摩下调瑞思迈 (RMD) 投资评级 指减肥药与竞品入市双重压制其增长空间","url":"https://stock-news.laohu8.com/highlight/detail?id=2644749109","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2644749109?lang=zh_cn&edition=full","pubTime":"2026-06-17 21:05","pubTimestamp":1781701559,"startTime":"0","endTime":"0","summary":"机构同步下调盈利测算与估值目标,报告测算瑞思迈2027 财年净利润同比增速约 5%,仅小幅高于市场 4% 的一致预期,远低于企业近三年 19% 的每股收益复合增速。该行将目标价自 286 美元下调至 230 美元,提示竞品回归、减重药物渗透将长期限制企业估值修复空间。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/NjViMmRjZjhjOGM5NGFlMzkzMTgwODQxMTc3.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/NjViMmRjZjhjOGM5NGFlMzkzMTgwODQxMTc3.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"301645","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4588","LU0170899867.USD","IE00B5TLWC47.USD","RMD","BK4567","LU2008162690.USD","LU2177674079.SGD","BK4548","BK4504","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111823360","title":"瑞思迈斥资3.4亿美元收购Noctrix Health,安杰利尼风投迎来首笔投资退出","url":"https://stock-news.laohu8.com/highlight/detail?id=1111823360","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111823360?lang=zh_cn&edition=full","pubTime":"2026-06-03 19:42","pubTimestamp":1780486964,"startTime":"0","endTime":"0","summary":"安杰利尼风投迎来了其投资组合中的首笔成功退出。医疗设备巨头瑞思迈已同意以高达3.4亿美元的全现金交易,收购专注于睡眠障碍治疗的初创公司Noctrix Health。交易完成后,瑞思迈将把Noctrix Health的技术整合进其现有的睡眠健康解决方案中,以加强其在睡眠呼吸暂停及其他睡眠障碍治疗领域的市场地位。Noctrix Health开发的创新神经刺激疗法,旨在为传统治疗方案效果不佳的患者提供新的选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4504","BK4567","IE00B5TLWC47.USD","BK4082","BK4585","LU2177674079.SGD","BK4548","LU2008162690.USD","RMD","BK4588","LU0170899867.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173709534","title":"异动解读|瑞思迈盘中下跌5.08%,宣布重大收购切入新赛道引发市场担忧","url":"https://stock-news.laohu8.com/highlight/detail?id=1173709534","media":"行情直击","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1173709534?lang=zh_cn&edition=full","pubTime":"2026-05-30 03:01","pubTimestamp":1780081295,"startTime":"0","endTime":"0","summary":"5月29日,瑞思迈盘中下跌5.08%,报193.08美元/股,成交额2.75亿美元。消息面上,公司宣布重大收购,作为医疗器械巨头正式切入新赛道。市场对此次收购反应偏负面,投资者担忧收购可能带来整合风险及短期资金压力,叠加当前股价已从52周高点293.81美元大幅回落,市场情绪较为脆弱。同行业中,美敦力跌1.98%、波士顿科学跌1.66%、雅培跌0.67%,板块整体承压。瑞思迈是全球领先的呼吸系统医疗设备及云端软件公司,主要诊断、治疗和管理睡眠呼吸障碍、慢性阻塞性肺病等慢性疾病。(以上内容均基于市场公开消息,由程序或算法智能生成,仅作为股价异动提醒,不作为投资建议或交易依据。)","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RMD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.resmed.com","stockEarnings":[{"period":"1week","weight":0.0755},{"period":"1month","weight":0.2116},{"period":"3month","weight":0.1479},{"period":"6month","weight":-0.0796},{"period":"1year","weight":-0.1722},{"period":"ytd","weight":-0.0178}],"compareEarnings":[{"period":"1week","weight":-0.002},{"period":"1month","weight":0.0365},{"period":"3month","weight":0.0206},{"period":"6month","weight":0.1111},{"period":"1year","weight":0.1921},{"period":"ytd","weight":0.1232}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"ResMed Inc.是一家特拉华州公司,成立于1994年3月。该公司在医疗设备和基于云的软件应用程序的开发、制造、分销和营销方面处于全球领先地位,这些应用程序诊断、治疗和管理呼吸系统疾病,包括睡眠呼吸障碍、慢性阻塞性肺病、神经肌肉疾病和其他慢性疾病。该公司的产品和解决方案旨在改善患者的生活质量,减少慢性病的影响,并降低医疗保健成本,因为全球医疗保健系统继续推动从医院到家庭和低成本环境的护理转移。该公司基于云的数字软件健康应用程序以及设备旨在提供联网护理,以改善患者的治疗效果并提高客户的效率。","yearOnYearQuotes":[{"month":1,"riseRate":0.709677,"avgChangeRate":0.025332},{"month":2,"riseRate":0.516129,"avgChangeRate":0.002251},{"month":3,"riseRate":0.580645,"avgChangeRate":0.012701},{"month":4,"riseRate":0.548387,"avgChangeRate":0.014374},{"month":5,"riseRate":0.612903,"avgChangeRate":0.008895},{"month":6,"riseRate":0.7,"avgChangeRate":0.040489},{"month":7,"riseRate":0.741935,"avgChangeRate":0.029736},{"month":8,"riseRate":0.625,"avgChangeRate":0.031945},{"month":9,"riseRate":0.387097,"avgChangeRate":0.015614},{"month":10,"riseRate":0.387097,"avgChangeRate":-0.004331},{"month":11,"riseRate":0.774194,"avgChangeRate":0.034364},{"month":12,"riseRate":0.580645,"avgChangeRate":0.018091}],"exchange":"NYSE","name":"瑞思迈","nameEN":"ResMed"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"瑞思迈(RMD)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供瑞思迈(RMD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"瑞思迈,RMD,瑞思迈股票,瑞思迈股票老虎,瑞思迈股票老虎国际,瑞思迈行情,瑞思迈股票行情,瑞思迈股价,瑞思迈股市,瑞思迈股票价格,瑞思迈股票交易,瑞思迈股票购买,瑞思迈股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"瑞思迈(RMD)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供瑞思迈(RMD)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}